P2RY12 and chronic kidney disease: On the other hand, Thomas et al. [142] evaluated the association between ABCD-GENE (age, body mass index, chronic kidney disease, diabetes, and CYP2C19 genetic variants) score and the effectiveness of clopidogrel vs. alternative P2Y12 inhibitor (prasugrel or ticagrelor) therapy after PCI.